Compare TRN & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRN | GPCR |
|---|---|---|
| Founded | 1933 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 1994 | 2023 |
| Metric | TRN | GPCR |
|---|---|---|
| Price | $34.09 | $41.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $34.00 | ★ $103.17 |
| AVG Volume (30 Days) | ★ 703.7K | 640.1K |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.03% | N/A |
| EPS Growth | ★ 85.98 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $2,156,900,000.00 | N/A |
| Revenue This Year | $1.91 | N/A |
| Revenue Next Year | $15.61 | N/A |
| P/E Ratio | $113.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.38 | $15.80 |
| 52 Week High | $37.36 | $94.90 |
| Indicator | TRN | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 55.62 | 54.44 |
| Support Level | $31.12 | $30.82 |
| Resistance Level | $35.33 | $57.23 |
| Average True Range (ATR) | 1.02 | 2.07 |
| MACD | 0.12 | 0.71 |
| Stochastic Oscillator | 82.73 | 73.02 |
Trinity Industries Inc sells and leases railroad products and railcar maintenance services in North America. The company operates under the name TrinityRail in two main segments: railcar leasing and management services, which owns railcars and provides fleet management and administration services; rail products, which builds, sells, and modifies freight and tank railcars and their components; and all other, which sells highway products such as guardrail and other highway barriers. Customers include railroads, leasing companies, and shipping companies in agriculture, construction, consumer products, energy, and chemicals.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.